Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
2005702 citationsPhilip J. Mease, Dafna D. Gladman et al.Arthritis & Rheumatismprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Mark Weinberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Weinberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Weinberg more than expected).
This network shows the impact of papers produced by Mark Weinberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Weinberg. The network helps show where Mark Weinberg may publish in the future.
Co-authorship network of co-authors of Mark Weinberg
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Weinberg.
A scholar is included among the top collaborators of Mark Weinberg based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Mark Weinberg. Mark Weinberg is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Genovese, Mark C., Philip J. Mease, G. T. D. Thomson, et al.. (2007). Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.. PubMed. 34(5). 1040–50.155 indexed citations
10.
Mease, Philip J., Ernest Choy, Dafna D. Gladman, et al.. (2005). 24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Lara D. Veeken. 44.
11.
Mease, Philip J., John T. Sharp, P A Ory, et al.. (2005). Adalimumab treatment effects on radiographic progression of joint disease in patients with psoriatic arthritis: Results from ADEPT. Annals of the Rheumatic Diseases. 64. 320–320.16 indexed citations
12.
Mease, Philip J., Dafna D. Gladman, Christopher T. Ritchlin, et al.. (2005). Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT. Research Portal (King's College London). 52(9).2 indexed citations
13.
Mease, Philip J., Dafna D. Gladman, Christopher T. Ritchlin, et al.. (2005). Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial. Arthritis & Rheumatism. 52(10). 3279–3289.702 indexed citations breakdown →
14.
Choy, Ernest, G. R. Burmester, Stefano Bombardieri, et al.. (2005). Efficacy of adalimumab in psoriatic arthritis as measured by the disease activity score 28. Research Portal (King's College London). 52(9).3 indexed citations
Kessler, Ada, Elka Miller, Arye Blachar, et al.. (2003). Mass at the Splenic Hilum. Journal of Ultrasound in Medicine. 22(5). 527–530.5 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.